1 Full title: HIV-1 RNA in Large and Small Plasmatic Extracellular

2 Vesicles: a Novel Parameter for Monitoring Immune Activation

3 and Virological Failure

4 Authors: Julien Boucher¹, Wilfried Wenceslas Bazié^{1, 2}, Benjamin Goyer¹, Michel

5 Alary^{3,4,5} and Caroline Gilbert^{1, 6*}

- 6 ¹ Axe de Recherche Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de
- 7 Québec-Université Laval, Québec, QC, Canada
- ² Programme de Recherche sur les Maladies Infectieuses, Centre Muraz, Institut National de
- 9 Santé Publique, Bobo-Dioulasso, Burkina Faso
- 10 ³ Axe de Recherche Santé des Populations et Pratiques Optimales en Santé, Centre de
- 11 Recherche du CHU de Québec-Université Laval, Québec, QC G1S 4L8, Canada;
- ⁴ Département de Médecine Sociale et Préventive, Faculté de Médecine, Université Laval,
- 13 Québec, QC G1V 0A6, Canada
- ⁵ Institut National de Santé Publique du Québec, Québec, QC G1V 5B3, Canada
- ⁶ Département de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine,
- 16 Université Laval, Québec, Canada
- 17 ***Correspondence:**
- 18 Caroline Gilbert (C.G.)
- 19 caroline.gilbert@crchudequebec.ulaval.ca (C.G.); Ph: +1-418-525-4444 ext. 46107; Fax: +1-
- 20 418-654-2765

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 Abstract

Background: Antiretroviral therapy (ART) suppresses viral replication in most people living 22 23 with HIV-1 (PLWH). However, PLWH remain at risk of viral rebound. HIV-1 infection modifies the content of extracellular vesicles (EVs). The changes in microRNA content in EVs 24 are biomarkers of immune activation and viral replication in PLWH. Moreover, viral molecules 25 are enclosed in EVs produced from infected cells. Our objective was to assess the value of EV-26 associated HIV-1 RNA as a biomarker of immune activation and viral replication in PLWH. 27 28 Methods: Plasma samples were obtained from a cohort of 53 PLWH with a detectable viremia. Large and small EVs were respectively purified by plasma centrifugation at 17,000 x g and by 29 precipitation with ExoQuickTM. HIV-1 RNA and microRNAs were quantified in the EV 30 31 subtypes by RT-aPCR. Findings: HIV-1 RNA content was higher in large EVs of ART-naive PLWH. Small EVs HIV-32 1 RNA was equivalent in ART-naive and ART-treated PLWH and positively correlated with 33 CD4/CD8 T cell ratio. In ART-naive PLWH, HIV-1 RNA content of large EVs correlated with 34 small EV-associated miR-29a, miR-146a and miR-155, biomarkers of viral replication and 35 36 immune activation. A receiver operating characteristics analysis showed that HIV-1 RNA in large EVs discriminated PLWH with a high CD8 T cell count. 37 Interpretation: HIV-1 RNA in large EVs was associated with viral replication and immune 38

activation biomarkers. Inversely, HIV-1 RNA in small EVs was related to immune
 restoration. Overall, these results suggest that HIV-1 RNA quantification in purified EVs could
 be a useful parameter to monitor HIV-1 infection.

42 **Funding:** Canadian Institutes of Health Research (CIHR) grants MOP-391232; MOP-188726;

43 MOP-267056 (HIV/AIDS initiative)

Keywords (3-5): extracellular vesicles subtypes, HIV-1 RNA, immune activation, virological
failure

46

47 **Research in context**

48 Evidence before this study

Antiretroviral therapy (ART) suppress viral replication to make HIV-1 infection manageable, 49 but fails to clear the virus from people living with HIV-1 (PLWH). Hence, the infection 50 becomes a chronic condition characterized by a dysfunction of the immune system caused by 51 repeated activation and a persistent risk of a resurgence of viral replication (viral rebound). New 52 53 biomarkers are required to improve the care of PLWH by identifying the individuals with a greater immune dysfunction and/or a higher risk of viral rebound. HIV-1 infection modifies the 54 abundance, size and content of plasmatic extracellular vesicles (EVs). Specific host microRNAs 55 56 enreichment in EVs correlates with immune activation and viral rebound. In addition, viral proteins and genomic material are found within EVs. Various EV subtypes are released by 57 infected cells, all using different biogenesis machinery. The distribution of HIV-1 RNA in EV 58 subtypes has never been assessed and this novel parameter could provide information on the 59 infection progression. 60

61 Added value of this study

This study provides the first quantification of HIV-1 RNA in two EV subtypes, large and small, 62 from the plasma of PLWH. Large EVs HIV-1 RNA was lower in ART-treated PLWH and 63 decreased with the duration of treatment. HIV-1 RNA associated to large EVs was a better 64 predictor of immune activation than the standard plasma viral load. Inversely, the HIV-1 RNA 65 concentration in small EVs was unaffected by ART and linked to better immune functions. 66 67 Overall, the results presented in this study suggest that HIV-1 RNA in large EVs originates from ongoing viral replication, while HIV-1 in small EVs is the produce of proviral 68 transcription. 69

70 Implications of all the evidence

The standard procedure for the clinical care of PLWH is to quantify HIV-1 RNA in the whole plasma, disregarding the context of its production. We show that the differential distribution of HIV-1 RNA in large and small EVs seems to be an indicator of disease progression. The purification of plasmatic EVs is considered as a non-invasive liquid biopsy to assess the progression of diseases. PLWH could benefit from the analysis of their plasmatic EVs to monitor the infection with an improved precision.

77 **1. Introduction**

Forty years have passed since the outbreak of the HIV-1 pandemic (1). The greatest progress in fighting HIV-1 infection was the discovery of molecules that inhibit HIV-1 replication (2). This led to the implementation of antiretroviral therapy (ART), which remains to this day the only way to manage HIV-1 infection (3). ART blocks HIV-1 replication in people living with HIV-1 (PLWH), but viral reservoirs persist. Consequently, ART must be taken daily by PLWH to avoid viral rebound and plasmatic viral load has to be measured every six months to ensure viremic control (4).

85

Virological failure is either caused by treatment resistance or loss of treatment adherence (5). 86 87 Due to virological failure, CD4 T lymphocyte count plummets and the treatments must be optimized (6). Some PLWH have a detectable low-level viremia defined as non-suppressible 88 viremia (NSV) (7, 8). Despite many years of ART, NSV occurs without the apparition of 89 treatment resistance, and cannot be suppressed by treatment intensification (9). NSV originates 90 from defective or replication-competent provirus transcriptional activity of infected T cell 91 92 clones rather than new infection events (7). PLWH with NSV have an immune activation level similar to ART-suppressed PLWH (10). To summarize, a positive viral load assay could 93 indicate an ongoing virus replication that requires immediate treatment optimization, or viral 94 expression from latently infected cells for which treatment optimization is unnecessary (8). 95 Thus, there is a need to understand better the mechanisms and the context behind detectable 96 viremia in PLWH to facilitate their clinical care (8). 97

98

In recent years, the roles of extracellular vesicles (EVs) as biomarkers and a non-invasive tool
to monitor the HIV-1 disease progression have emerged (11-13). EVs are nanoparticles
enclosed by a bilayered lipid membrane (14). They are separated into two major subclasses

depending on their origin. The first class, microvesicles, is named large EVs in this article. 102 103 Large EVs are the product of the membrane budding (15). The second class is exosomes, called small EVs in this paper. Small EVs originate from the inward budding of endosomes and are 104 105 released in the extracellular environment when endosomes merge with the plasma membrane (16). The endosomal sorting complex required for transport (ESCRT) machinery is the major 106 107 pathway of small EVs biogenesis (16). Cargo selection in EVs subtypes is simultaneously a 108 passive and active process. It is passive because cytoplasm and membrane content can be randomly selected in EVs. As a result, component concentration in EVs changes according to 109 cellular expression. The EV biogenesis machinery drives the active cargo selection process. 110 111 Consequently, active cargo selection varies between EV subtypes and can increase cargo concentration independently of cellular expression changes (17). 112

113

114 HIV-1 infection modifies the host microRNA content of EVs (18). Enrichment of miR-29a, miR-146a and miR-155 in small EVs of PLWH under ART was a predictor of detectable 115 viremia (12). MiR-155 in large EVs of PLWH under ART was a predictor of immune activation 116 (19). MiR-155-enriched EVs enhanced HIV-1 infection and promoted inflammation in 117 118 recipient cells (18). Due to the similarities between EVs and HIV-1 biogenesis, infected cells 119 release EVs harbouring viral RNA and proteins (20, 21). The unspliced genomic RNA of HIV-1 and the transactivation response element (TAR) RNA sequence were measured in the EVs 120 released by infected cells (20-22). Inhibition of the ESCRT pathway lowers HIV-1 RNA 121 122 concentration in EVs, showing its role in viral RNA sorting to EVs (22). Moreover, HIV-1 RNA in EVs persists despite ART, even when the plasma viral load is indetectable (23). 123

124

125 Since EV subtypes have different biogenesis pathways and we have shown differential 126 biomarker roles for large and small plasmatic microRNA in EVs, we hypothesized that ART

- 127 influences the viral RNA distribution in both EVs subtypes of PLWH. This new measurement
- 128 could be a future biomarker for HIV infection management. The present study showed that
- 129 large EVs were more abundant and contained more HIV-1 RNA in ART-naive PLWH and
- 130 HIV-1 RNA in small EVs was unaffected by ART but correlated with the CD4/CD8 ratio.

131 **2. Methods**

132 **2.1 Study participants**

The cohort of PLWH present in this study (n = 53) was selected from a larger cohort of PLWH recruited in Bobo-Dioulasso and Ouagadougou (Burkina Faso) (12, 19, 24). These participants were selected because they had a detectable plasma viral load at their recruitment. All participants were anonymous volunteers and provided written informed consent.

137

138 2.2 Plasma EVs purification

Plasma EVs purification was performed according to a well-established procedure (11, 24, 25). 139 Platelet-free plasma (250 µL) was thawed at room temperature and treated with proteinase K 140 (1.25 mg/mL) for 10 minutes at 37 °C to eliminate protein aggregates and extravesicular RNA. 141 Then, the plasma was centrifuged at 3,000 x g for 15 minutes to discard apoptotic vesicles, and 142 at $17,000 \times g$ for 30 minutes to pellet large EVs. The remaining supernatant was mixed with 63 143 µL ExoQuickTM (System Biosciences) reagent and incubated at 4 °C overnight. A centrifugation 144 at $1,500 \times g$ for 30 minutes precipitated small EVs. EV pellets were washed with 0.22 μ m 145 filtered PBS and resuspended in 250 µL of 0.22 µm filtered PBS. 146

147

148 **2.3 Hydrodynamic size measurement**

Quality, homogeneity and size of EV samples were analyzed by dynamic light scattering (DLS)
with a Zetasizer Nano ZS (Malvern Instruments). Hydrodynamic diameter measurements were
done in duplicate at room temperature.

153 **2.4 EV quantification by flow cytometry**

Absolute EVs quantification by flow cytometry was performed as previously described (12). EVs were stained with lipophilic carbocyanine DiD dye and CellTraceTM CFSE (ThermoFisher Scientific), at a final concentration of 5 μ M. DiD+ and CFSE+ events were considered EVs. EV concentration in our samples was determined with 15 μ m silica beads (Polybead® Microspheres, Polysciences). The acquisition was performed on a modified BDFACS canto II with a photomultiplicator on the forward scatter (FSC) channel to improve nanoparticle detection.

161

162 **2.5 RNA extraction**

163 RNA was extracted from 50 μ L of purified EVs (diluted in three volumes of Trizol® LS 164 (ThermoFisher Scientific) using the phenol/chloroform method and resuspended in 15 μ L of 165 Tris/EDTA buffer (18, 26). RNA concentration was measured using a BioDropTM 166 spectrophotometer (Montreal Biotech Inc.).

167

168 2.6 HIV-1 RNA quantification

RT-PCR was performed on 5 µL of RNA with the Superscript IV reverse transcriptase kit 169 (ThermoFisher Scientific) according to the manufacturer instructions with a final concentration 170 of 10nM of primer set on a GeneAmp® PCR System 9700 (Applied Biosystems) (27). The 171 primers obtained from Integrated DNA Technologies: forward: 5'-172 were GCCTCAATAAAGCTTGCCTTGA-3'; reverse: 5'- GGCGCCACTGCTAGAGATTTT -3' to 173 174 target the 3' LTR region of the HIV-1 genome (NCBI accession number: K03455.1). CDNA was pre-amplified as described before (28). QPCR reactions were performed with the 175 QuantiTech SyBr Green kit (Qiagen) according to the manufacturer's instructions on a CFX384 176 Touch Real-Time PCR Detection System (Bio-Rad) (28). 177

178

179 2.7 MiRNA quantification by RT-qPCR

- 180 Reverse transcription was achieved using the miScript RT kit (Qiagen) in a GeneAmp® PCR
- 181 System 9700 (Applied Biosystems) (18). Quantitative PCR was conducted in 96-well plates
- 182 (Multiplate[™], BioRad[©]) with miScript SyBr[®] Green from Qiagen[©] using a CFX Connect[™]
- 183 Real-time system (Bio-Rad[©]). The primers for miR-29a (Cat: MS00003262), miR-146a (Cat:
- 184 MS00006566) and miR155 (Cat: MS00031489) were purchased from Qiagen[©].

185

186 **2.8 Statistical analysis**

187 Normal and lognormal distribution tests were carried out for all data sets. Data sets with a
188 lognormal distribution were transformed to obtain a normal distribution for statistical analysis.
189 Statistical analyses were carried out using GraphPad Prism software version 10.2.2 with p190 values below 0.05 considered statistically significant.

192 **3. Results**

193 **3.1 HIV-1 RNA and microRNA distribution in large and small plasmatic EVs**

194 of PLWH

The distribution of viral RNA between large and small EVs and the impact of ART treatment 195 were analyzed in a cohort of 53 PLWH with detectable viral load. Clinical characteristics 196 presented in Table 1 show that 14 were ART-naive and 39 were ART-treated. The median age 197 of ART-naive and ART-treated participants was 37 (interquartile range (IQR) 28-43) and 32 198 (27-43), respectively (p = 0.4165). ART-naive participants were living with HIV-1 for a median 199 200 duration of 5 months (IQR 1-51) and ART-treated for 26 (IQR 10-43) (p = 0.2497). Treated 201 participants were receiving ART for 24 months (IQR 7-66). The median CD4 T cell count, CD8 T cell count, and CD4/CD8 ratio were respectively 607 (IQR 264-762), 837 (IQR 515-1043) 202 and 0.7 (IQR 0.4-1.2) for ART-naive participants and 332 (IQR 182-469), 667 (IQR 522-926) 203 and 0.5 (IQR 0.2-0.7) for ART-treated participants. The plasma viral load median was higher 204 for the ART-Naive at 18,622 copies/mL (IQR 4,472-55,063) than for the ART-treated 205 participants at 9,373 (300-52,038). 206

207 Table 1. Characteristics of the study participants.208

	ART-Naive (n = 14)	ART (n = 39)	<i>p</i> -value
Men, n (%)	5 (35.7)	19 (48.7)	
Women, n (%)	9 (64.3)	20 (51.3)	
Age (years); median (IQR)	37 (28-43)	32 (27-43)	0.4165
HIV duration (months); median (IQR)	5 (1-51)	26 (10-43)	0.2497
CD4 T cells/µL; median (IQR)	607 (264-762)	332 (182-469)	0.0467
CD8 T cells/µL; median (IQR)	837 (515-1043)	667 (522-926)	0.6006
CD4/CD8 ratio; median (IQR)	0.7 (0.4-1.2)	0.5 (0.2-0.7)	0.0403
ART duration (month); median (IQR)	NA	24 (7-66)	
Plasma viral load (copies/mL); median (IQR)	18,622 (4,472-55,063)	9,373 (300-52,038)	0.6159

ART: antiretroviral therapy; IQR: Interquartile range; NA: not applicable

Large and small EVs were purified from the plasma of PLWH with a detectable viral load as 209 210 previously described (11, 12). As expected, large EVs from ART-naive PLWH (324 ± 31 nm) and ART-treated (364 ± 24 nm) had a bigger hydrodynamic diameter than the small EVs of 211 ART-naive PLWH (86 \pm 8.9 nm) and ART-treated (87 \pm 4.8 nm) (Figure 1A). Absolute 212 quantification by flow cytometry revealed that ART-naive PLWH large EVs were more 213 concentrated (1.52 x $10^7 \pm 1.80$ x 10^6 EVs/mL) than ART-treated PLWH (8.46 x $10^6 \pm 1.15$ x 214 10⁶ EVs/mL) (Figure 1B). In addition, ART did not affect the count of small EVs since ART-215 naive PLWH small EVs were at a concentration of $1.76 \times 10^7 \pm 3.51 \times 10^6$ EVs/mL and ART-216 treated PLWH small EVs concentration was $1.35 \times 10^7 \pm 2.67 \times 10^6$ EVs/mL (Figure 1B). 217



218 219

Figure 1. Viral RNA distribution in plasmatic EV subtypes from PLWH.

EVs were purified from platelet-free and proteinase K-treated plasma by centrifugation at 17,000 x g to pellet large 220 EVs, followed by ExoQuick precipitation to obtain small EVs. A. EV hydrodynamic size measurement by dynamic 221 222 light scattering. B. Large and small EVs absolute concentration was determined by flow cytometry. C. Comparison 223 of large and small EV-associated HIV-1 in ART-naive and ART-treated PLWH. D. The number of copies of HIV-

1 RNA per mL of sample was divided by the number of EVs per mL of sample to estimate the number of HIV-1 224 copies per EV. Statistical analysis was carried out by one-way ANOVA (* p < 0.05; ** p < 0.01; **** p < 0.0001). 225

- ART: antiretroviral therapy; EV: extracellular vesicles; PLWH: people living with HIV-1. 226
- 227

Then, HIV-1 RNA was quantified by RT-qPCR in both types of EVs. HIV-1 RNA 228 concentration was higher in large EVs (1.48 x $10^5 \pm 4.02$ x 10^4 copies/mL) and small EVs (1.07 229 x $10^5 \pm 2.09$ x 10^4 copies/mL) than in the plasma (5.57 x $10^4 \pm 1.61$ x 10^4 copies/mL) (Figure 230 S1). The difference between ART-treated (2.72 x $10^5 \pm 1.24$ x 10^4 copies/mL) and ART-naive 231 PLWH (1.03 x $10^5 \pm 3.05$ x 10^4 copies/mL) was most notable in large EVs (Figure 1C). HIV-1 232 RNA concentration in small EVs was similar in ART-naive $(1.41 \times 10^5 \pm 6.02 \times 10^4 \text{ copies/mL})$ 233 and ART-treated PLWH (9.49 x $10^4 \pm 1.87$ x 10^4 copies/mL) (Figure 1C). With absolute EV 234 concentrations, HIV-1 RNA copies per EV was calculated. In terms of HIV RNA per EV, 235 differences between ART-naive (large: 0.021 ± 0.007 copies/mL; small: 0.014 ± 0.007 236 copies/mL) and ART-naive PLWH (large: 0.017 ± 0.005 copies/mL; small: 0.011 ± 0.003 237 238 copies/mL) were minimal (Figure 1D). Thus, the higher HIV-1 RNA content in large EVs of ART-naive PLWH was likely the result of increased production of large EVs containing HIV-239 1 RNA rather than the enrichment of HIV-1 RNA in large EVs. The results showed that ART 240 241 decreased HIV RNA concentration in large EVs.

242

We previously showed a link between viral rebound and immune activation in PLWH and miR-243 29a, miR-146a and miR-155 content in plasmatic EVs (12, 19). Quantification of three 244 microRNAs in large and small EVs by RT-qPCR showed that miR-155 was predominant in 245 large EVs of ART-naive PLWH (Figure S2A-B), while miR-146 and miR-29a were 246 significantly enriched in small EVs (Figure S2C-F). A correlation analysis showed that large 247 EVs and small EVs HIV-1 RNA in ART-naïve PLWH correlated with miR-29a, miR-146 and 248 to a lesser extent with miR-155 concentration in small EVs (Figure 2A and C). These results 249 strengthened the viral rebound biomarker potential of miRNAs in small EVs. Conversely, in 250

251 ART-treated PLWH, no correlation was found between large or small EVs HIV-1 RNA and

small EVs miRNA content (Figure 2B and D). In addition, no correlation was found between 252

large or small EVs HIV-1 RNA and large EVs miRNA content (Figure S3). 253



254 255

Figure 2. Separated correlation analysis between EV-associated viral load and miRNAs in ART-receiving 256 and ART-naive PLWH.

257 EVs were purified from platelet-free and proteinase K-treated plasma by centrifugation at $17,000 \times g$ to pellet large 258 EVs, followed by ExoQuick precipitation to obtain small EVs. Viral load and miRNAs content in EVs were 259 quantified by RT-qPCR in large and small EVs. A. Correlation analysis between HIV-1 RNA concentration in 260 large EVs and miRNAs concentration in small EVs of ART-naive PLWH. B. Correlation analysis between HIV-261 1 RNA concentration in large EVs and miRNAs concentration in small EVs of PLWH under ART. C. Correlation 262 analysis between HIV-1 RNA concentration and miRNAs concentration in small EVs of ART-naive PLWH. D. 263 Correlation analysis between HIV-1 RNA concentration and miRNAs concentration in small EVs of PLWH under 264 ART. ART: antiretroviral therapy; EV: extracellular vesicles; PLWH: people living with HIV-1.

All rights reserved. No reuse allowed without permission.

267 3.2 HIV-1 RNA in plasmatic EV subtypes of PLWH is associated with

268 biomarkers of HIV-1 pathogenesis

Correlation analysis between large and small EVs HIV-1 RNA content and clinical parameters was performed to determine if HIV-1 RNA quantification in EVs is a better predictor of disease progression than the conventional plasma measurement. HIV-1 RNA measurement in the plasma correlated with the large EVs HIV-1 RNA measurement (Figure 3A). In ART-treated PLWH, large EVs HIV-1 RNA diminished with time under ART (Figure 3B). Conversly, in small EVs, HIV-1 RNA concentration was unaffected by ART (Figures 1C and 3B) There was a positive association between HIV-1 RNA in small EVs and the CD4/CD8 ratio (Figure 3C).



276 277

Figure 5. Correlation analysis between EV-associated HTV-1 KNA and biomarkers of infection progression.
 EVs were purified from platelet-free and proteinase K-treated plasma by centrifugation at 17,000 x g to pellet large

279 EVs, followed by ExoQuick precipitation to obtain small EVs. HIV-1 RNA was quantified by RT-qPCR in large

and small EVs. A. Correlation analysis between the plasma viral load and the purified EV-associated viral load.
 B. Correlation analysis between the time receiving ART and plasma and EVs HIV-1 RNA. C. Correlation between

the CD4/CD8 ratio and plasma and EVs viral load. ART: antiretroviral therapy; EV: extracellular vesicles.

284	Next, we evaluated the potential of EV-associated HIV-1 RNA as a parameter to discriminate
285	PLWH with immune activation and dysfunction. Among the 53 participants, those with a CD8
286	T cell count above 500 cells/ μ L were designated with immune activation (n = 41). The
287	remaining participants with a CD8 T cell count below 500 cells/ μ L were in the control group
288	(n = 12). A receiver operating characteristics (ROC) curve analysis was performed to determine
289	which HIV-1 RNA concentration in the plasma, large EVs or small EVs discriminates PLWH
290	with immune activation. HIV-1 RNA in the plasma (AUC = 0.50 ; 95% CI = $0.29-0.71$; p =
291	0.9661) (Figure 4A) and the small EVs (AUC = 0.62 ; 95% CI = $0.43-0.80$; p = 0.2257) (Figure
292	4C) could not distinguish PLWH with immune activation. HIV-1 RNA concentration in large
293	EVs had the best diagnosis performance (AUC = 0.66 ; 95% CI = $0.50-0.83$; p = 0.0852) (Figure
294	4B). PLWH with a CD4 count below 500 cells/ μ L (n = 38) or a CD4/CD8 ratio below 1 (n =
295	45) was designated with immune impairment. The participants with a CD4 T cell count above
296	500 cells/ μ L (n = 15) or a CD4/CD8 ratio above 1 (n = 8) were the controls. HIV-1 RNA in the
297	plasma discriminated PLWH with immune impairment (Figure S4A and D), while HIV-1 RNA
298	in large (Figure S4B-E) and small EVs (Figure S4C-F) did not. Overall, HIV-1 RNA in the
299	plasma discriminated PLWH with low CD4 T cell count and CD4/CD8 ratio, while HIV-1 RNA
300	in large EVs best discriminated PLWH with high CD8 T cell count.



301 302

Figure 4. Diagnosis performance of immune activation by HIV-1 RNA concentrations in the plasma and 303 EVs subtypes.

304 HIV-1 RNA concentrations in the plasma and EV subtypes were used for ROC analysis to discriminate participants 305 with immune activation. The participants with a CD8 T cell count below 500/µL were the controls. A CD8 T cell 306 count above 500/µL defined immune activation. A. ROC curve of HIV-1 RNA concentration in the plasma. B. 307 ROC curve of HIV-1 RNA concentration in large EVs. C. ROC curve of HIV-1 RNA concentration in small EVs.

308 **ROC: Receiver Operating Characteristics**

309

310 **4. Discussion**

Decades of suppressive ART fails to clear viral reservoirs. Hence, PLWH are permanently at risk of viral rebound (4). When viremia is detected in PLWH, ART regimen modification or intensification is not always necessary and characterization of the virus in the plasma of PLWH could assist in HIV-1 infection management (8). This study aimed to quantify HIV-1 RNA in both types of plasmatic EVs of PLWH towards a more personalized HIV-1 infection management. We found that the value of small and large EV-associated HIV-1 RNA are biomarkers of disease progression and viral replication.

318

319 We previously reported an increase in total EVs concentration in ART-naive PLWH (13). Here, 320 only the large EVs concentration was higher in ART-naive PLWH than PLWH under ART. Our results suggest that large EVs probably caused the increase in total EV concentration 321 observed by Hubert et al. (13). The large EVs HIV-1 RNA level was higher in ART-naive 322 PLWH than in treated PLWH. In PLWH under ART, HIV-1 RNA in large EVs was negatively 323 324 correlated with time under ART. Interestingly, HIV-1 RNA concentration in small EVs was unaffected by ART. The persistence of HIV-1 RNA in small EVs despite ART is reminiscent 325 of NSV, which is unaffected by ART (9). NSV has been more associated with men (29). Our 326 327 results showed that men's small EVs were richer in HIV-1 RNA than women's (Figure S5). This data suggests again that the HIV-1 RNA in small EVs could be linked to NSV. 328

329

HIV-1 RNA in large EVs was susceptible to treatment, suggesting it is the product of active
viral replication. These observations corroborate the previous assessment of viral RNA in large
and small EVs in humanized mice (28). In that study, mice treatment lowered HIV-1 RNA in
large EVs only. HIV-1 RNA in humanized mice small EVs correlated positively with the CD4

and CD4/CD8 ratio. The same correlation was observed in PLWH small EVs with a positive 334 335 CD4/CD8 ratio. Viral replication causes a loss of CD4 T lymphocytes and expansion of CD8 T lymphocytes (6, 30). This strengthens the hypothesis that HIV-1 RNA in small EVs is not the 336 337 product of viral replication. The hypothesis that large EVs contain HIV-1 RNA from active viral replication and small EVs contain HIV-1 RNA from provirus transcription could be 338 explored by RNA sequencing. Viral replication will result in more genetic diversity due to the 339 340 error-prone reverse transcriptase (31). On the contrary, HIV-1 RNA from NSV is less diverse since it comes from the transcriptional activity of clonally expanded CD4 T lymphocytes (7, 341 32). The Nanopore sequencing technology efficiently detects genetic divergence caused by 342 343 viral replication (33) and mutations associated with ART resistance (34). Nanopore additionally offers the possibility to sequence the full length HIV-1 genome (35). This novel technology 344 could further characterize the viral RNA associated with EVs subtypes. 345

346

This is the first report of comparative HIV-1 RNA quantification in EV subtypes of PLWH. 347 348 Viral proteins and genetic material have been generally linked to small EVs (exosomes) because their biogenesis intertwines (36). Viruses can be formed in multivesicular bodies with exosomes 349 350 (37). HIV-1 assembly also occurs at the plasma membrane (38). Both secretion mechanisms 351 are involved in viral replication in infected cells but their relative contribution to HIV-1 pathogenesis has never been explored. Different biogenesis machinery incorporates disparate 352 RNA and microRNA content in large and small EVs (39). This could explain the differential 353 354 distribution of HIV-1 RNA in large and small EVs among PLWH. In addition, viruses would be associated with different host components whether they form at the plasma membrane or in 355 multivesicular bodies. For example, miR-155 is enriched in large EVs during HIV-1 infection, 356 promoting viral replication in the recipient cell (18). Therefore, viruses related to large EVs 357 could be more infectious due to miR-155 transfer. 358

- In this study, we showed a differential distribution of HIV-1 RNA in plasmatic EVs subtypes of PLWH. Viral replication was linked to HIV-1 RNA in large EV. Besides, HIV-1 RNA in small EVs was associated with immune restoration. This novel parameter could help us predict HIV-1 infection progression in PLWH and decipher the cause of a viral rebound. Combined with a miRNA analysis, we could establish a nucleic acid profile in EVs associated with
- immune dysfunction and virological failure to improve PLWH monitoring.

366	Author contributions: Conceived and designed the experiments J.B., W.W.B., B.G. and C.G.:
367	Performed the experiments: J.B., W.W.B. and B.G. Analyzed the data: J.B., W.W.B., B.G. and
368	C.G.; Contributed clinical samples, reagents, materials, and analytical tools: J.B., W.W.B. M.A.
369	and C.G.; Wrote the manuscript: J.B. and C.G. All authors have critically reviewed the paper
370	and have agreed on the published version of the manuscript.
371	
372	Competing interests:
373	The authors declare that the research was conducted without any commercial or financial
374	relationships construed as a potential conflict of interest.
375	
376	Acknowledgements: This research was funded through Canadian Institutes of Health Research
377	(CIHR) grants MOP-391232; MOP-188726; MOP-267056 (HIV/AIDS initiative) to C.G. J.B.
378	and W.B.B. are the recipient of the Desjardins scholarship from the Fondation du CHU de
379	Québec. J.B. and W.B.B. are recipients of the recruitment scholarship from the AIDS Research
380	Fund of Université Laval. W.W.B. is the recipient of the leadership and sustainable
381	development scholarship and the Fonds de Recherche du Québec - Santé (FRQ-S) doctoral
382	training scholarship. The FRQ-S supports the Centre de recherche du CHU de Québec -
383	Université Laval infrastructure. The authors thank Drs. Martin Pelletier and Stephane Gobeil
384	for access to the qPCR platform. We are very grateful to the study participants, without whom
385	this study would not have been feasible.

386

Institutional review board statement: The study was conducted according to the guidelines
of the Declaration of Helsinki and approved by the Centre de Recherche du CHU de QuébecUniversité Laval (Québec, QC, Canada) ethics review boards C12-03-208 (2012-2021) and

CER-2019-4258. All subjects were volunteers and provided written informed consent beforeparticipating in the study.

392

393 Informed consent statement: Written informed consent was obtained from all subjects394 involved in the study.

395

396 Data availability statement:

The study protocol, results and informed consent documents will be made available to researchers upon request from the corresponding author. Researchers will be asked to complete a concept sheet for their proposed analyses to be reviewed, and the investigators will consider the overlap of the proposed project with active or planned analyses and the appropriateness of the study data for the proposed analysis.

All rights reserved. No reuse allowed without permission.

403 **Bibliography**

Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a
 T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).
 Science. 1983;220(4599):868-71.

407 2. Gupta PK, Saxena A. HIV/AIDS: Current Updates on the Disease, Treatment and Prevention.
408 Proc Natl Acad Sci India Sect B Biol Sci. 2021;91(3):495-510.

409 3. Sankaranantham M. HIV - Is a cure possible? Indian J Sex Transm Dis AIDS. 2019;40(1):1-5.

4. Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, et al. Rebound of 411 plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV 412 reservoir: implications for eradication. Aids. 2010;24(18):2803-8.

413 5. Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes DR, et al. Antiretroviral drug 414 resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line 415 therapy. The Journal of infectious diseases. 2011;204(4):515-20.

Gupta-Wright A, Fielding K, van Oosterhout JJ, Alufandika M, Grint DJ, Chimbayo E, et al.
Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi:
an observational cohort study. The Lancet HIV. 2020;7(9):e620-e8.

419 7. White JA, Wu F, Yasin S, Moskovljevic M, Varriale J, Dragoni F, et al. Clonally expanded HIV-1
420 proviruses with 5'-leader defects can give rise to nonsuppressible residual viremia. J Clin Invest.
421 2023;133(6).

422 8. Wu F, Simonetti FR. Learning from Persistent Viremia: Mechanisms and Implications for 423 Clinical Care and HIV-1 Cure. Curr HIV/AIDS Rep. 2023;20(6):428-39.

424 9. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al. Treatment
425 intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral
426 therapy. Proc Natl Acad Sci U S A. 2009;106(23):9403-8.

427 10. Mohammadi A, Etemad B, Zhang X, Li Y, Bedwell GJ, Sharaf R, et al. Viral and host mediators
428 of non-suppressible HIV-1 viremia. Nat Med. 2023;29(12):3212-23.

429 11. Bazié WW, Boucher J, Vitry J, Goyer B, Routy JP, Tremblay C, et al. Plasma Extracellular
430 Vesicle Subtypes May be Useful as Potential Biomarkers of Immune Activation in People With HIV.
431 Pathog Immun. 2021;6(1):1-28.

432 12. Bazié WW, Boucher J, Traoré IT, Kania D, Somé DY, Alary M, et al. Vesicular MicroRNA as
433 Potential Biomarkers of Viral Rebound. Cells. 2022;11(5).

Hubert A, Subra C, Jenabian MA, Tremblay Labrecque PF, Tremblay C, Laffont B, et al.
Elevated Abundance, Size, and MicroRNA Content of Plasma Extracellular Vesicles in Viremic HIV-1+
Patients: Correlations With Known Markers of Disease Progression. Journal of acquired immune
deficiency syndromes (1999). 2015;70(3):219-27.

438 14. Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal
439 information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J
440 Extracell Vesicles. 2024;13(2):e12404.

Tricarico C, Clancy J, D'Souza-Schorey C. Biology and biogenesis of shed microvesicles. Small
GTPases. 2017;8(4):220-32.

443 16. Han Q-F, Li W-J, Hu K-S, Gao J, Zhai W-L, Yang J-H, et al. Exosome biogenesis: machinery, 444 regulation, and therapeutic implications in cancer. Molecular Cancer. 2022;21(1):207.

44517.Dixson AC, Dawson TR, Di Vizio D, Weaver AM. Context-specific regulation of extracellular446vesicle biogenesis and cargo selection. Nature Reviews Molecular Cell Biology. 2023;24(7):454-76.

Boucher J, Rousseau A, Boucher C, Subra C, Bazié WW, Hubert A, et al. Immune Cells Release
MicroRNA-155 Enriched Extracellular Vesicles That Promote HIV-1 Infection. Cells. 2023;12(3).

449 19. Bazié WW, Boucher J, Goyer B, Traoré IT, Kania D, Somé DY, et al. Plasma vesicular miR-155

450 as a biomarker of immune activation in antiretroviral treated people living with HIV. Front Immunol.

451 2022;13:916599.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.01.24316593; this version posted November 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

452 20. Narayanan A, Iordanskiy S, Das R, Van Duyne R, Santos S, Jaworski E, et al. Exosomes derived 453 from HIV-1-infected cells contain trans-activation response element RNA. J Biol Chem. 454 2013;288(27):20014-33. 455 21. Columba Cabezas S, Federico M. Sequences within RNA coding for HIV-1 Gag p17 are 456 efficiently targeted to exosomes. Cellular Microbiology. 2013;15(3):412-29. 457 22. Barclay RA, Schwab A, DeMarino C, Akpamagbo Y, Lepene B, Kassaye S, et al. Exosomes from 458 uninfected cells activate transcription of latent HIV-1. J Biol Chem. 2017;292(28):11682-701. 459 23. Hladnik A, Ferdin J, Goričar K, Deeks GS, Peterlin MB, Plemenitaš A, et al. Trans-Activation 460 Response Element RNA is Detectable in the Plasma of a Subset of Aviremic HIV-1-Infected Patients. 461 Acta Chim Slov. 2017;64(3):530-6. 462 24. Bazié WW, Boucher J, Goyer B, Kania D, Traoré IT, Somé DY, et al. HIV Replication Increases 463 the Mitochondrial DNA Content of Plasma Extracellular Vesicles. Int J Mol Sci. 2023;24(3). 464 Bazié WW, Goyer B, Boucher J, Zhang Y, Planas D, Chatterjee D, et al. Diurnal Variation of 25. 465 Plasma Extracellular Vesicle Is Disrupted in People Living with HIV. Pathogens. 2021;10(5). 466 26. Rio DC, Ares M, Jr., Hannon GJ, Nilsen TW. Purification of RNA using TRIzol (TRI reagent). Cold 467 Spring Harb Protoc. 2010;2010(6):pdb.prot5439. 468 27. Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, et al. Transfer and evaluation 469 of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of 470 human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin 471 Microbiol. 2005;43(6):2709-17. 472 Boucher J, Pépin G, Goyer B, Hubert A, Bazié WW, Vitry J, et al. Exploring the Relationship 28. 473 Between Extracellular Vesicles, the Dendritic Cell Immunoreceptor and MicroRNA-155 in an In Vivo 474 Model of HIV-1 Infection to Understand the Disease and Develop New Treatments. bioRxiv. 475 2024:2024.10.18.619157. 476 Cyktor JC, Bosch RJ, Mar H, Macatangay BJ, Collier AC, Hogg E, et al. Association of Male Sex 29. 477 and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-478 Term Antiretroviral Therapy. The Journal of infectious diseases. 2021;223(3):462-70. 479 30. Eller Michael A, Goonetilleke N, Tassaneetrithep B, Eller Leigh A, Costanzo Margaret C, 480 Johnson S, et al. Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection. Journal of 481 virology. 2016;90(8):4005-16. 482 31. O'Neil PK, Sun G, Yu H, Ron Y, Dougherty JP, Preston BD. Mutational analysis of HIV-1 long 483 terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II 484 to viral mutagenesis. J Biol Chem. 2002;277(41):38053-61. 485 32. Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, et al. HIV latency. Specific HIV 486 integration sites are linked to clonal expansion and persistence of infected cells. Science. 487 2014;345(6193):179-83. 488 33. Ode H, Matsuda M, Shigemi U, Mori M, Yamamura Y, Nakata Y, et al. Population-based 489 nanopore sequencing of the HIV-1 pangenome to identify drug resistance mutations. Scientific 490 reports. 2024;14(1):12099. 491 34. Park SY, Faraci G, Ganesh K, Dubé MP, Lee HY. Portable Nanopore sequencing solution for 492 next-generation HIV drug resistance testing. J Clin Virol. 2024;171:105639. 493 35. Wright IA, Delaney KE, Katusiime MGK, Botha JC, Engelbrecht S, Kearney MF, et al. NanoHIV: 494 A Bioinformatics Pipeline for Producing Accurate, Near Full-Length HIV Proviral Genomes Sequenced 495 Using the Oxford Nanopore Technology. Cells. 2021;10(10). 496 36. Meng B, Ip NCY, Abbink TEM, Kenyon JC, Lever AML. ESCRT-II functions by linking to ESCRT-I 497 in human immunodeficiency virus-1 budding. Cellular Microbiology. 2020;22(5):e13161. 498 37. Pelchen-Matthews A, Kramer B, Marsh M. Infectious HIV-1 assembles in late endosomes in 499 primary macrophages. J Cell Biol. 2003;162(3):443-55. 500 38. Ono A, Freed EO. Plasma membrane rafts play a critical role in HIV-1 assembly and release. 501 Proc Natl Acad Sci U S A. 2001;98(24):13925-30.

- 502 39. Crescitelli R, Lässer C, Szabó TG, Kittel A, Eldh M, Dianzani I, et al. Distinct RNA profiles in
- subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. J Extracell 503 504 Vesicles. 2013;2.